Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (Review)

Emmanuele Venanzi Rullo, Manuela Ceccarelli, Fabrizio Condorelli, Alessio Facciolà, Giuseppa Visalli, Francesco D'Aleo, Ivana Paolucci, Bruno Cacopardo, Marilia Rita Pinzone, Michele D.I. Rosa, Giuseppe Nunnari, Giovanni F. Pellicanò

Risultato della ricerca: Contributo su rivistaArticolo di reviewpeer review

Abstract

Despite the profound changes and improvements reached in the field of HIV treatment, tolerability and adherence to highly active antiretroviral therapy remains a challenge. Furthermore, multi-experienced patients could take advantage of drugs with different mechanisms of action to combat the spread of resistance to actual therapy. For these reasons identification of new HIV drugs is crucial. Among all the molecules that at present are under investigation, entry and fusion inhibitors pose an interesting class owing to their peculiar characteristics, including prevention of entry of the virus into the human cells. In this study, we reviewed articles, clinical trials, and conference communications about all the drugs under investigation belonging to the class of entry and fusion inhibitors that are at least in phase I clinical trials.

Lingua originaleInglese
pagine (da-a)1987-1995
Numero di pagine9
RivistaMolecular Medicine Reports
Volume19
Numero di pubblicazione3
DOI
Stato di pubblicazionePubblicato - 2019

Fingerprint

Entra nei temi di ricerca di 'Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (Review)'. Insieme formano una fingerprint unica.

Cita questo